The syndecan-1 heparan sulfate proteoglycan is a viable target for myeloma therapy.
Yang Y, MacLeod V, Dai Y, Khotskaya-Sample Y, Shriver Z, Venkataraman G, Sasisekharan R, Naggi A, Torri G, Casu B, Vlodavsky I, Suva LJ, Epstein J, Yaccoby S, Shaughnessy JD Jr, Barlogie B, Sanderson RD.
Yang Y, et al.
Blood. 2007 Sep 15;110(6):2041-8. doi: 10.1182/blood-2007-04-082495. Epub 2007 May 29.
Blood. 2007.
PMID: 17536013
Free PMC article.